Premium
Discrepancies in potency assessment of recombinant FVIII concentrates
Author(s) -
Lee C. A.,
Kessler C. M.,
Varon D.,
Martinowitz U.,
Heim M.,
BARROWCLIFFE T. W.,
RAUT S.,
HUBBARD A. R.
Publication year - 1998
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1046/j.1365-2516.1998.440634.x
Subject(s) - medicine , potency , recombinant dna , virology , genetics , in vitro , gene , biology
Summary. Results of assays of recombinant FVIII concentrates have been reviewed over a 10‐year period. Initially there was wide variability between laboratories but this was minimised by the development of standardised assay methodology, in particular the use of haemophilic plasma for pre‐dilution and 1% albumin in assay buffers. Using this standardised methodology and concentrate standards, there were no major diferences in potency between one‐stage, two‐stage, and chromogenic assays on the two full‐length recombinant FVIII concentrates. However, using a plasma standard, the chromogenic method gave much higher potencies than the one‐stage method on the same concentrates, and this explains a similar discrepancy found in patients' post‐infusion samples after injection of recombinant concentrates. It is suggested that concentrate standards be used for such post‐infusion samples in order to minimise this discrepancy.